In the Materials section, compound 1 should be 4- methoxybenzyl (6R,7R)-3-(chloromethyl)-8-oxo-7-(2-phenylacetamido)- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. Discrepancies uncovered in follow-up studies lead to the reevaluation of NDM-1-containing strains. The conclusions of the original manuscript remain unchanged, but the following figures and tables should be updated with values for the correct NDM-1-containing strains. Figure 2: The concentration of PcephPT after incubation with E. coli MG1655 expressing NDM-1 was 45 ± 3 μM after 1 h and 4 ± 6 μM after 20 h. Table 2: PcephPT did not fully inhibit the growth of either NDM-1 strain; values of 17.5 μM for PcephPT in MG1655 are more accurately described as MIC90 (compound only) and MIC60 (+Cu), while analogous entries for UTI89 NDM-1 reflect MIC60 and MIC70, respectively. PT in UTI89 had an MIC of 17.5 μM. Table 3: PcephPT inhibited the NDM-1 copAΔ strain with an MIC60 of 8.8 μM (compound alone); MIC of PcephPT + Cu was 17.5 μM, with an MIC80 of 1.1 μM. Figure 4: CFU/mL for the MG1655 NDM-1 strain was >12 500 when treated with PT and 0-500 when treated with PT + Cu. Figure S9: CFU/mL for the UTI89 NDM-1 strain were 4500-8500 when treated with PT and 0-500 when treated with PT + Cu. Cells treated with PcephPT ± Cu were not spotted due to high MICs. 0 h CFU/mL values: MG1655 NDM-1 = 1 100 000; UTI89 NDM-1 = 940 000.
ASJC Scopus subject areas
- Infectious Diseases